Treatment with cyclic-RGD-PLGC(Me)AG-MMAE-ACPP resulted in complete tumor regression in one quarter of MDA-MB-231 tumor bearing mice, compared to no survival in the control groups. This rational mechanism for amplified delivery of imaging and potent chemotherapeutic agents avoids the use of ...
在初步诊断为广泛期SCLC时,18%的患者有脑转移且2年后增至约80%。EORTC(European Organization for Research and Treatment of Cancer)的一项研究,将对化疗有反应的患者随机化分为2组,接受PCI或不接受PCI,发现PCI治疗组1年生存率为27.1%,未接受PCI者为13.3%。[49]在该研究中,PCI不仅减少脑转移的发生率也提高无...
ZEPZELCA®(lurbinectedin) is a prescription medicine used to treat adults with a kind of lung cancer called small cell lung cancer (SCLC). ZEPZELCA may be used when your lung cancer: has spread to other parts of the body (metastatic),and ...
small cell lung cancer; treatment Abstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in the world. ...
Small-cell lung cancer is divided into two stages: Limited.The tumor is in only one side of your chest, the tissues between your lungs, and nearby lymph nodes. Extensive.Cancer has spread to other parts of your body. Small-Cell Lung Cancer Treatment ...
For more than three decades, care for small-celllung cancer(SCLC) remained mostly the same. That’s changing now -- doctors have a new option called immunotherapy. This line of treatment uses your body’s own immune system to fight cancer. ...
Find out about TECENTRIQ® (atezolizumab) for the treatment of extensive-stage small cell lung cancer (ES-SCLC). See full safety for more information.
Figure 3. Relevant ongoing clinical trials assessing the efficacy of immune checkpoint inhibitors either as consolidation treatment or concurrent with chemoradiotherapy in limited-stage (LD) small cell lung cancer (SCLC). cCT-RT, concurrent chemotherapy plus radiotherapy; HR, hazard ratio; OS, overall...
Navigating treatment combinations in small-cell lung cancer The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it co...
类器官Small Cell Lung Cancer 类器官(Organoids)是指将成体干细胞或多能干细胞在体外三维培养形成的具有一定空间结构的组织类似物。类器官在组织结构、细胞类型、自我更新能力和功能等方面与来源组织高度一致,从而在发育生物学、疾病造模、精准医学、药物研发、基因和细胞疗法、感染和免疫以及再生医学等生物医学的多个领...